Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Frankfurt
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

Columbia Laboratories Inc

+ Add to Watchlist

CLB1:GR

5.729 EUR 0.126 2.25%

As of 03:20:01 ET on 03/27/2015.

Snapshot for Columbia Laboratories Inc (CLB1)

Open: 5.660 Day's Range: 5.660 - 5.738 Volume: 0
Previous Close: 5.603 52wk Range: 4.279 - 7.683 1-Yr Rtn: +10.96%

Stock Chart for CLB1

No chart data available.
  • CLB1:GR 5.729
  • 1D
  • 1M
  • 1Y
5.603
Interactive CLB1 Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for CLB1

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) 178.4502
Relative P/E vs. DAX -
Earnings Per Share (USD) (ttm) -
Est. EPS (USD) (12/2015) 0.0350
Est. PEG Ratio -
Market Cap (M EUR) 61.73
Shares Outstanding (M) 10.78
30 Day Average Volume 8
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend (USD) 1.0000
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 04/29/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for CLB1

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for CLB1

Columbia Laboratories, Inc. is an international pharmaceutical company that develops and markets women's health care and endocrinology products. The Company develops products intended to treat infertility, dysmenorrhea, endometriosis, and hormonal deficiencies, primarily utilizing its Bioadhesive Delivery System technology. Columbia markets Striant, and Prochieve 8% and 4%.

Frank C Condella JrPresident/CEOGeorge O ElstonChief Financial Officer
Nikin PatelCEO:Molecular ProfilesAmy RaskopfManager:Investor Relations
More Company Profile & Key Executives for CLB1

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil